Insulin Resistance News and Research

RSS

Insulin Resistance is a condition in which the body does not respond to insulin properly. This is most common in Type II diabetes or associated with obesity, ketoacidosis, infection, and certain rare conditions. Diminished effectiveness of insulin in lowering blood glucose levels requiring 200 units or more of insulin per day to prevent hyperglycemia or ketosis.

Researchers find link between hepatic steatosis and carotid lesions

Nonalcoholic fatty liver disease (NAFLD) is often caused by abdominal obesity, which is also one of the main causes of insulin resistance and metabolic syndrome. The latter, in turn, is an important cardiovascular risk factor, and has been found to be associated with the presence of carotid atherosclerotic lesions.

24 Oct 2009

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. ISIS 113715 is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). The study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control.

22 Oct 2009

Bioidentical Hormones for breast cancer prevention

For a sample of prevention awareness on Breast Cancer and overall health, there are key terms one is suggested to start on: BRCA; DHEA; Estradiol; Estriol; Free radicals; Insulin resistance; Melatonin; Premarin; Progesterone; SHBG; vitamin D.

22 Oct 2009

Wellstat Therapeutics and Sanofi-Aventis to develop, manufacture and commercialize PN2034

Wellstat Therapeutics Corporation and sanofi-aventis announced today a global licensing agreement to develop, manufacture and commercialize PN2034, a first-in-class oral insulin sensitizer for the treatment of Type II diabetes.

21 Oct 2009

Metabolic master switch sets the biological clock in body tissues

Our body's activity levels fall and rise to the beat of our internal drums-the 24-hour cycles that govern fundamental physiological functions, from sleeping and feeding patterns to the energy available to our cells. Whereas the master clock in the brain is set by light, the pacemakers in peripheral organs are set by food availability. The underlying molecular mechanism was unknown.

19 Oct 2009

Study shows type 2 diabetes patients treated with ACTOplus met experience blood sugar reduction

A study, published online in the journal Current Medical Research and Opinion, showed that a greater percentage of patients with type 2 diabetes treated with the fixed-dose combination ACTOplus met® (pioglitazone HCl and metformin HCl) as initial therapy reached the study goal of hemoglobin A1c (HbA1c) of less than or equal to 7 percent compared to either component alone.

15 Oct 2009

Increase in adiponectin hormone levels protects against sepsis-related mortality

A hormone naturally found in the fat that surrounds the abdominal organs for the first time has been linked to death related to sepsis, surgeons reported at the 2009 Clinical Congress of the American College of Surgeons. A study exhibited at the conference showed that low levels of the hormone adiponectin placed animals at a profoundly high risk of death from a septic insult.

14 Oct 2009

Merck Frosst Canada's JANUMET receives Notice of Compliance in Canada

Merck Frosst Canada Ltd. announced today that its new diabetes treatment, JANUMET(TM) (sitagliptin/metformin HCI, MSD), has received Notice of Compliance (NoC) in Canada.

13 Oct 2009

AHA: Americans should reduce their calorie intake to combat obesity and cardiovascular disease

Reaching for that chocolate chip cookie? Think twice. The American Heart Association (AHA) just released the strictest guidelines ever for added sugars, recommending Americans limit their diet to 100 calories (6 teaspoons) for women and 150 calories (nine teaspoons) for men each day.

13 Oct 2009

Arena Pharmaceuticals to present Phase 3 BLOSSOM trial results at Obesity 2009

Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that lorcaserin will be featured in multiple presentations at Obesity 2009, the 27th Annual Scientific Meeting of The Obesity Society in Washington, DC.

12 Oct 2009

Antioxidants can contribute to early onset of Type 2 diabetes

An international team of scientists, led by Monash University researchers, has found that anti-oxidants commonly touted for their health-promoting benefits, could contribute to the early onset of Type 2 diabetes.

8 Oct 2009

Low levels of ROS might protect us from diabetes, says study

We've all heard about the damage that reactive oxygen species (ROS) - aka free radicals - can do to our bodies and the sales pitches for antioxidant vitamins, skin creams or "superfoods" that can stop them. In fact, there is considerable scientific evidence that chronic ROS production within cells can contribute to human diseases, including insulin resistance and type 2 diabetes.

7 Oct 2009

Fat and muscle mass may contribute to diabetes risk

Fat and muscle mass, as potentially determined by a person's ethnic background, may contribute to diabetes risk, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

6 Oct 2009

Bristol-Myers Squibb and AstraZeneca receive marketing authorisation for ONGLYZA in Europe

Bristol-Myers Squibb Company and AstraZeneca announced today that the European Commission has granted marketing authorisation for ONGLYZATM in the 27 countries of the European Union.

5 Oct 2009

Dapagliflozin with metformin reduces glycosylated hemoglobin level and body weight

Results from a 24-week phase 3 clinical study demonstrated that the investigational drug dapagliflozin, added to metformin, demonstrated significant mean reductions in the primary endpoint, glycosylated hemoglobin level (HbA1c) and in the secondary endpoint, fasting plasma glucose (FPG) in patients with type 2 diabetes inadequately controlled with metformin alone, as compared to placebo plus metformin.

3 Oct 2009

Metabolic syndrome related to elevated levels of liver enzymes in obese teenagers

Researchers studying a large sample of adolescent American boys have found an association between metabolic syndrome, which is a complication of obesity, and elevated liver enzymes that mark potentially serious liver disease.

30 Sep 2009

Januvia in combination with metformin or taken alone lowers blood sugar

A post-hoc analysis, presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD), of data pooled from studies of 104 weeks in duration showed ‘Januvia’ (sitagliptin), when taken alone or in combination with metformin, provided significant blood sugar lowering over two years.

29 Sep 2009

Increasing insulin levels can aid muscle building in the elderly

Recently, scientists have recognized that loss of responsiveness to insulin plays a major role in the loss of physical strength that occurs as people grow older. Now, University of Texas Medical Branch at Galveston researchers have demonstrated that by increasing insulin levels above the normal range in elderly test subjects, they can restore the impaired muscle-building process responsible for age-related physical weakness.

28 Sep 2009

Rosiglitazone slows progression of cachexia in cancer affected mice

Insulin resistance, the hallmark of type 2 diabetes and a condition often associated with obesity, is paradoxically also an apparent contributor to muscle wasting and severe fat loss that accompanies some cancers, according to new research.

27 Sep 2009

European CHMP recommends Merck's JANUVIA and JANUMET as add-on to insulin

Merck & Co., Inc., which operates in many countries as Merck Sharp & Dohme (MSD), has received a positive opinion from the European Medicines Agency’s (EMEA) Committee for Medicinal Products for Human Use (CHMP) for JANUVIA® tablets and JANUMET® tablets recommending their use as add-on to insulin for the treatment of type 2 diabetes.

26 Sep 2009